Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26673641
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Gastrointest+Tumors
2015 ; 2
(1
): 33-40
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Gut Microbiota and Hepatocellular Carcinoma
#MMPMID26673641
Tao X
; Wang N
; Qin W
Gastrointest Tumors
2015[May]; 2
(1
): 33-40
PMID26673641
show ga
BACKGROUND: Hepatocellular carcinoma (HCC) is a common complication of liver
diseases such as those related to viral hepatitis and liver cirrhosis. The
gut-liver axis is gaining increasing attention as a key pathophysiological
mechanism responsible for the progression of HCC. Here, we will review the data
from the published literature to address the association between HCC and gut
microbiota. SUMMARY: The presence of high levels of endotoxemia in the blood
results in portal hypertension and ensuing hepatocyte damage, thus leading to the
development of HCC. Probiotics can be used to treat or prevent the progression of
HCC, because they may decrease the counts of gut microbiota and thus improve the
endotoxemia. KEY MESSAGE: Increased bacterial translocation can result in
endotoxemia, which may play a critical role in the progression of HCC. Modulation
of the gut microbiota by probiotics may represent a new avenue for therapeutic
intervention in HCC. PRACTICAL IMPLICATIONS: Breakdown in intestinal barrier
function and bacterial overgrowth are main events in the development of HCC. When
the intestinal barrier function is disrupted, large amounts of bacterial products
can enter the liver and induce inflammation through their receptors, leading to
liver diseases. Altering the gut microflora has been proposed as an adjunctive
therapy to reduce bacterial translocation and prevent progression of HCC. The
purpose of this review is to discuss the relationship between gut microbiota and
HCC in both pathogenesis and treatment by probiotics.
free
free
free
